Avoiding-immune-destruction

Avoiding Immune Destruction (免疫破壊の回避)

定義と現象

腫瘍細胞が免疫系の認識・排除から逃れる多様な機構の総称。Hanahan の Hallmarks 2.0 (Cell 2011) で 8 番目の hallmark として正式に追加され、ICI (immune checkpoint inhibitor) 革命によってがん治療パラダイムの中心となった概念。Schreiber & Old らが提唱した cancer immunoediting 3 phase model (elimination → equilibrium → escape) で時間軸を含めた dynamic process として整理される (Schreiber et al. Science 2011)。

2024 年に Galassi et al. は既存の「3 つの E」を治療標的の観点から再分類し、「3 つの C (Camouflage・Coercion・Cytoprotection)」 フレームワークを提唱した (Galassi et al. CancerCell 2024)。(1) Camouflage (偽装) は抗原提示欠陥・APC 招集障害・免疫排除を含み、(2) Coercion (強制) は PD-L1 過剰発現・cGAS-STING サイレンシング・代謝的免疫抑制からなり、(3) Cytoprotection (細胞保護) はパーフォリン/グランザイム耐性・アポトーシス閾値上昇を担う。各「C」に対応する承認薬・開発中薬剤が整理され、ICI 耐性解析の統合的参照枠として機能する。

臨床的に問題となる escape phase では、腫瘍は (1) 抗原性低下、(2) inhibitory checkpoint 活性化、(3) 免疫抑制 TME 構築、(4) エフェクター分子への抵抗性獲得という 4 軸で immune surveillance を回避する。近年、染色体レベルの異常 — 全ゲノム倍加 (WGD: whole-genome doubling) — も重要な逃避機構として同定されており、WGD 後のコハク酸蓄積がヒストン脱メチル化酵素 KDM6 活性を低下させ、H3K27me3 増加を介して MHC クラス I 転写を抑制するという代謝-エピジェネティック連鎖が乳がんで実証された (Foidart et al. CancerCell 2026)。

Cancer immunoediting の 3 phase

1. Elimination (immune surveillance): innate (NK / γδT / macrophage) + adaptive (CD8+ T) 免疫が transformed cell を認識・排除
2. Equilibrium (dormancy): 排除されない腫瘍が低レベルで持続、免疫圧で clonal selection が進行
3. Escape: immune-resistant clone が outgrowth、臨床的に detectable な腫瘍として顕在化

このフレームワークは Schreiber らが Nature 2007 でレビュー、ICI 治療の理論的基盤として citation 多数。

主要回避機構

抗原提示の喪失

• B2M / HLA-A/B/C 変異・喪失: MHC class I down-regulation で CD8+ T cell 認識が失敗。NSCLC では ICI resistant 例で B2M LOF 変異が enrichment (B2M entity 参照)
• 抗原 processing 欠陥: TAP1/2、tapasin の欠失
• HLA-E up-regulation: NKG2A inhibitory receptor を介した NK 抑制

Immune checkpoint exploitation

• PD-L1 (CD274) up-regulation: IFN-γ 応答性または oncogene-driven (EGFR / ALK / KRAS-driven) で発現亢進、CD8+ T cell の PD-1 を engage して exhaustion 誘導 → anti-PD-1/PD-L1 治療標的
• CTLA-4: priming phase で T cell 活性化を抑制 → ipilimumab / tremelimumab 標的
• TIGIT / LAG-3 / TIM-3 / VISTA: 次世代 checkpoint 標的、relatlimab (anti-LAG-3) 承認、tiragolumab (anti-TIGIT) 開発中
• NKG2A: HLA-E engagement で NK 抑制 → monalizumab 開発中

免疫抑制 TME 構築

• MDSC (myeloid-derived suppressor cells): G-MDSC / M-MDSC が arginase / iNOS / ROS 産生で T cell 抑制
• Treg (regulatory T cells): TGF-β / IL-10 / CTLA-4 / 細胞間接触で effector T 抑制
• TAM (tumor-associated macrophages): M2-skewed macrophage が IL-10 / TGF-β / arginase で抑制
• TAN (tumor-associated neutrophils): N2-polarized neutrophil + Neutrophil-extracellular-traps (NET) による T cell 機能阻害 (NET-mediated immune suppression は NETosis-cancer-metastasis でも記述)
• 代謝的抑制: adenosine (CD39-CD73 axis)、kynurenine (IDO1)、PGE2 (COX2)、tryptophan 枯渇
• TGF-β / IL-10 cytokine milieu: 直接的 effector cell 抑制

NK 認識回避

• MICA/MICB shedding: ADAM10/17 による NKG2D ligand cleavage (詳細 NKG2D-MICA-MICB-pathway)
• EV-mediated decoy: 腫瘍由来エクソソーム (cancer-extracellular-vesicles) 上の MICA/B / PD-L1 が effector cell receptor を decoy
• Exosomal PD-L1: 詳細 Exosomal-PD-L1 参照

治療パラダイム

Class	代表薬	標的
Anti-PD-1	pembrolizumab、nivolumab、cemiplimab	T cell exhaustion 解除
Anti-PD-L1	atezolizumab、durvalumab、avelumab	tumor / immune cell PD-L1
Anti-CTLA-4	ipilimumab、tremelimumab	priming phase Treg / Teff balance
Anti-LAG-3	relatlimab	exhaustion 補完
Anti-TIGIT	tiragolumab	CD226 axis 復活
Anti-NKG2A	monalizumab	NK / CD8+ T cell 復活
CAR-T / TIL / NK-cell-therapy	cellular therapy	adoptive transfer
TGF-β trap	bintrafusp alfa (PD-L1×TGF-βRII)	TME suppression 解除
Bispecific T cell engager	tarlatamab (DLL3xCD3)	redirect T cell

バイオマーカー

• PD-L1 IHC (TPS / CPS): TKI 適応の primary biomarker、NSCLC で TPS≥50% で pembrolizumab monotherapy 適応
• TMB (tumor mutational burden): neoantigen 量の surrogate、NSCLC で TMB-H>10 mut/Mb
• MSI / MMR: tissue-agnostic ICI 適応
• 腫瘍浸潤 CD8+ T 密度: prognostic + predictive
• gene expression signature: T cell-inflamed gene expression profile (TIS)、IFN-γ signature

関連エンティティ・概念

• Checkpoint genes: PD-L1 / PD-1 / CTLA-4 / TIGIT / LAG-3 / B2M
• Pathways: CTLA-4-B7-signaling-pathway / PD-1/PD-L1 axis / NKG2D-MICA-MICB-pathway
• Concept: Hallmarks-of-cancer / Tumor-promoting-inflammation / NETosis-cancer-metastasis / Exosomal-PD-L1 / NK-cell-therapy
• MOC: cancer-biology / cancer-neutrophils / lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 187 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Zhu et al. JImmunotherCancer 2026 — Spatial immune atlas of breast cancer brain metastasis reveals CD163
• Vilarino et al. MolCancer 2026 — NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFNgamma

Basic-Extracellular vesicles

• Fan et al. CancerCell 2026 — Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways
• Hendrix et al. CancerCell 2026 — Extracellular vesicles whisperers of tumor immune evasion
• Cai et al. MolCancer 2026 — Extracellular vesicles in solid tumors from tumor ecology to engineered therapeutics

Basic-Immunotherapy

• Foidart et al. CancerCell 2026 — Whole-genome doubling drives immune evasion by silencing antigen presentation
• Chemla et al. Cell 2026 — HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion
• Cremasco et al. CellRep 2026 — Natural killer cells swarm and cross-recruit cytotoxic T cells via CCR5
• Mao et al. FrontImmunol 2026 — MicroRNA-targeted reprogramming of CD8+ T cells against cancer
• Huang et al. NatBiomedEng 2026 — Programmable mRNA 3utr engineering restores MHC-I and overcomes immune evasion in prostate cancer
• Lu et al. NatRevCancer 2026 — Opportunities and challenges of targeting cGAS-STING in cancer
• Bianca et al. NatRevImmunol 2026 — CRISPR screen reveals regulators of age-associated cd8+ t cell dysfunction in cancer
• Elahi et al. NatRevImmunol 2026 — Immune regulation by erythroid cells how erythroid progenitor cells and mature red blood cells shape immunity

Basic-Neutrophil and myeloid cell

• Wang et al. JClinInvest 2026 — A CD138+ tumor-associated macrophagesiglec-f+ neutrophil feed-forward loop promotes immune evasion in pancreatic cancer
• Redavid et al. JImmunotherCancer 2026 — Targeting macrophage-driven NK cell immunosuppression to improve cancer immunotherapy
• Wang et al. NatCancer 2026 — CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8
• Kerndl et al. NatImmunol 2026 — Monocyte infiltration induces CNS arginine catabolism to fuel neuroinflammation

Basic-Oncogene and genetics

• Wong et al. Cell 2026 — A recipe for chaos extrachromosomal DNA and the hallmarks of cancer
• Yang et al. CellRep 2026 — Pan-cancer evolution signatures link clonal expansion to dynamic changes in the tumor immune microenvironment
• Liu et al. FrontImmunol 2026 — Pan-cancer analysis of OSR2 with a focus on underlying mechanisms and therapeutic implications in lung adenocarcinoma

Basic-Others

• Winslow et al. CancerDiscov 2026 — A roadmap to transform lung cancer outcomes priorities in biology, therapeutic innovation, early detection, prevention
• Chen et al. JImmunotherCancer 2026 — Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of
• Jimenez-Castano et al. NatCancer 2026 — Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity

Basic-Tumor microenvironment

• Kirschstein et al. CancerCell 2026 — Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer
• Lichun et al. NatCancer 2026 — Cellular neighborhoods in cancer
• Wang et al. NatCancer 2026 — TGFbeta induces an atypical EMT to evade immune mechanosurveillance in lung adenocarcinoma dormant metastasis

Clinical-NSCLC-EGFR

• Niu et al. FrontImmunol 2026 — Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following

Clinical-Novel modalities

• Kubo et al. BioProtocol 2026 — Cite as kubo, N. et al. (2026). A feeder cell-free system for chimeric antigen receptor gene transduction into
• Moreno et al. LancetRegHealthEur 2026 — Advances in cell therapy for solid tumours european perspective and future directions

Clinical-SCLC

• Campisi et al. CancerCell 2026 — Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer

合成 (Outputs)

• immunosuppressive-niche-single-target-phase1